Abstracts tagged "Gene Expression"

Abstract Number: 2069 • 2015 ACR/ARHP Annual Meeting
High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)
K Ranade, L Wang, P Brohawn, W Greth, J Drappa and G Illei, MedImmune, Gaithersburg, MD
Background/Purpose: Increased expression of genes inducible by type 1 interferons has been observed in a subset of patients with systemic lupus erythematosus (SLE). Oral corticosteroids…
Abstract Number: 3128 • 2015 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis
Paula S. Ramos¹, Thomas A. Medsger Jr.² and Carol A. Feghali-Bostwick¹, ¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The etiology and mechanisms underlying the wide variation in disease heterogeneity and severity in systemic sclerosis (SSc) remain unknown. To assess the role of…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 2098 • 2015 ACR/ARHP Annual Meeting
Prioritizing Likely Causative Genes in Genome-Wide Association Studies (GWAS) Identified Risk Loci for Immune-Mediated Inflammatory Disorders Using Cell-Type Specific Expression Quantitative Loci (eQTL) Information
Elisa Docampo¹, Ming Fang¹, Julia Dmitrieva¹, Emilie Théâtre¹, Mahmoud Elansary¹, Rob Mariman¹, Ann-Stephan Gori¹, Myriam Mni¹, François Crins², Wouter Coppieters², Edouard Louis³ and Michel Georges¹, ¹Unit of Animal Genomics, GIGA-R Université de Liège, Liège, Belgium, ²GenoTranscriptomics platform, GIGA-R Université de Liège, Liège, Belgium, ³Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium
<h1> Background/Purpose: </h1> Immune-mediated inflammatory disorders (IMIDs) share many genetic risk factors. Pleiotropy may exist at different levels and most of the underlying mechanisms are…
Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting
Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Shervin Assassi¹, Maureen D Mayes¹, Claudia Pedroza², Jeffrey T. Chang², Daniel E. Furst³, Leslie J. Crofford⁴, Richard Nash⁵, Peter McSweeney⁵, Mary Ellen Csuka⁶, Ellen Goldmuntz⁷, Lynette Keyes-Elstein⁸, Paul Wallace⁹ and Keith Sullivan¹⁰, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, Vanderbilt University, Nashville, TN, ⁵Colorado Blood Cancer Institute, Denver, CO, ⁶Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, ⁷NIAID, National Institutes of Health, Bethesda, MD, ⁸Rho Federal Systems, Inc., Chapel Hill, NC, ⁹Roswell Park, Buffalo, NY, ¹⁰Duke University, Durham, NC
Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
Abstract Number: 2686 • 2014 ACR/ARHP Annual Meeting
Gene Array Analysis Reveals Unique Estrogen Signature in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus
Stephanie Amici¹, Nicholas A. Young², Lai-Chu Wu², Mireia Guerau¹ and Wael N. Jarjour³, ¹Health and Rehab Sciences, The Ohio State University, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disorder predominately affecting females in the reproductive age range. Estrogen is present at higher levels in this…
Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
Mate Ongenaert¹, Sonia Dupont², Béatrice Vayssière², Reginald Brys¹, Luc Van Rompaey¹, Christel Menet¹ and René Galien², ¹Galapagos NV, Mechelen, Belgium, ²Galapagos SASU, Romainville, France
Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…
Abstract Number: 2680 • 2014 ACR/ARHP Annual Meeting
DNA Hydroxymethylation Changes in CD4+T Cells from Patients with Systemic Lupus Erythematosus
Ming Zhao, Wei Liao, Bochen Zhu, Ruifang Wu and Qianjin Lu, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose Recent studies have uncovered 5-hydroxymethylcytosine (5hmC) as the sixth base of the genome, and that the Ten-eleven translocation (TET) family proteins is responsible for…
Abstract Number: 1211 • 2014 ACR/ARHP Annual Meeting
Gene Expression Profile in Muscle Tissue before and after Immunosuppressive Treatment in Patients with Myositis
Joan Raouf¹, Ingela M. Loell², Yi-Wen Chen³, Rongye Shi⁴, Inger Nennesmo⁵, Helene Alexanderson⁶, Maryam Dastmalchi², Marina Korotkova⁷, Kanneboyina Nagaraju^8,9 and Ingrid E. Lundberg^10,11, ¹Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, ⁴Research Center for Genetic Medicine, Childrens National Medical Center, Research Center for Genetic Medicine, Washington DC, USA, Washington DC, WA, ⁵Institution for Laboratory Medicine (LABMED), Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden, Stockholm, Sweden, ⁶Karolinska Institutet, Department of medicine, Rheumatology Unit, Karolinska Universitetssjukhuset Solna, Stockholm, Sweden, Stockholm, Sweden, ⁷Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁸Genetic Medicine, Children's National Medical Center, Washinton D C, DC, ⁹Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ¹⁰Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Autoimmune muscle diseases such as polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of inflammatory cells, production of cytokines and chemokines, as well…
Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments
Yoshinobu Koyama¹, Motohiko Tanino², Shuji Nagano³, Toshiyuki Ota³ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Yokohama, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…
Abstract Number: 1136 • 2014 ACR/ARHP Annual Meeting
Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter
David B. Mount^1,2, Tony R. Merriman³, Eli A. Stahl⁴, Hyon K. Choi⁵ and Asim Mandal¹, ¹Renal Division, Brigham and Women's Hospital, Boston, MA, ²Renal Division, VA Boston Healthcare System, Boston, MA, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴Mt Sinai School of Medicine, New York City, NY, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Variation in SLC2A9, which encodes the urate transporter GLUT9, is the major single genetic determinant of serum uric acid (SUA); however, the causal variant(s)…
Abstract Number: 2460 • 2014 ACR/ARHP Annual Meeting
Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4⁺ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis
Amy E. Anderson¹, Arthur G Pratt¹, Mamdouh Sedhom², Nisha Nair³, Jonathan Massey³, Christine Routledge¹, Ben Hargreaves¹, Philip Brown¹, Anne Barton⁴, John D Isaacs¹ and Ranjeny Thomas², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Translational Research Institute, The University of Queensland Diamantina Institute, Queensland, Australia, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Early diagnosis of rheumatoid arthritis (RA) improves outcomes but is challenging, particularly amongst anti-citrullinated peptide auto-antibody (ACPA) negative individuals. Previously we identified an IL-6…
Abstract Number: 1135 • 2014 ACR/ARHP Annual Meeting
Genes Involved in Cartilage Synthesis and Risk to Knee Osteoarthritis
Abhishek Mishra Sr., Rajeshwar Srivastava II, Divya Sanghi III, Ajai Singh IV and Devendra Parmar V, Deptt of Orthopaedic Surgery, King George's Medical University,, Lucknow, India
Background/Purpose Osteoarthritis (OA), characterized by gradual loss of articular cartilage in the joint, is a leading cause of disability among the elderly people. Though the…
Abstract Number: 2220 • 2014 ACR/ARHP Annual Meeting
Overexpression of Ankyrin Repeat Domain Containing Protein 1 Gene (ANKRD1) in Polymyositis Muscle Biopsies Is Correlated to Hypoxia
Samuel Katsuyuki Shinjo¹, Sueli Mieko Oba-Shinjo², Miyuki Uno² and Suely Kazue Nagahashi Marie², ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: ANKRD1 codes for ankyrin repeat domain containing protein 1, which belongs to the muscle ankyrin repeat protein family involved in a mechano-signaling pathway that…
Abstract Number: 1002 • 2014 ACR/ARHP Annual Meeting
Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression
Matlock A. Jeffries^1,2, Madison Donica³, Anand Annan⁴, Michael Stevenson⁵, Mary Beth Humphrey^6,7, Judith A. James^6,8 and Amr H. Sawalha⁹, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Pathol;ogy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Rheumatology/Immunology/Arthritis Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Osteoarthritis (OA) is the leading cause of chronic disability affecting 40% of individuals over the age of 70 and costing $128 billion annually in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].